USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
XECHEM, INC.
Address:
NEW BRUNSWICK TECHNOLOGY CENTER
100 JERSEY AVENUE, BLDG. B-310
NEW BRUNSWICK, NJ 08901
Phone:
(732) 247-3300
URL:
N/A
EIN:
363696864
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $845,739.00 6

Award List:

DEVELOPMENT OF HYDROHEPTIN, AN ANTIFUNGAL ANTIBIOTIC

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,680.00
Agency:
HHS
Principal Investigator:
Ramesh C Pandey
Abstract:
The incidence of fungal infection has been steadily increasing among immunosuppressed and cancer patients. for this reason, there is a need for an effective, non-toxic water soluble antifungal agent. the objective of this research is to prepare and characterize the novel antifungal antibiotic… More

HYBRID PROCESSOR FOR PHYSIOLOGICAL ARTIFACT DETECTION HYBRID PROCESSOR FOR PHYSIOLOGICAL ARTIFACT DETECTION

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,680.00
Agency:
NASA
Principal Investigator:
Abstract:
N/a

ENHANCED XECHEM INTEGRATED SCREENING TECHNIQUE (EXISTTM)

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$86,742.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

BIOACTIVE NATURAL PRODUCTS FROM MARINE EXTREMOPHILES

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$87,084.00
Agency:
HHS
Principal Investigator:
Ramesh C. Pandey
Abstract:
Not Available An autonomous field of sensor nodes needs to acquire and track targets of interest traversing the field. Small detection ranges limit the detectability of the field. As detections occur in the field, detections are transmitted acoustically to a master node. Both detection processing… More

NIPRISAN FOR TREATING PATIENTS WITH SICKLE CELL DISEASE

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$99,372.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sickle Cell Disease (SCD) is a hereditary blood disorder caused by an abnormal hemoglobin called sickle hemoglobin (Hb S). Although the Hb S of patients with SCD in the steady state can transport oxygen like normal hemoglobin, Hb S forms rigid fibers when the… More

Toxicity Studies of Potent Antisickling Agent 5HMF

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$473,181.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a hereditary blood disorder, affecting millions of patients worldwide, leading to high medical costs and a shortened life expectancy. Although many approaches to prevent the symptoms of sickle cell disease (SCD) have been and… More